Loading
A phase 3 trial of Camrelizumab and Rivoceranib (apatinib) in gastric & gastro-oesophageal junction cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC is a phase 3 interventional study registered as NCT04342910 by Jiangsu HengRui Medicine Co., Ltd., with 550 participants planned, started 2020-09-21 and due to reach its primary completion in 2026-04-01. Interventions recorded: camrelizumab, Apatinib Mesylate, Paclitaxel and Irinotecan.
Shares Camrelizumab, Jiangsu Hengrui Pharmaceuticals, Immune checkpoint inhibitors and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Anti-angiogenic therapy, Small-molecule kinase inhibitors, Immune checkpoint inhibitors and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Anti-angiogenic therapy, Immune checkpoint inhibitors and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Small-molecule kinase inhibitors and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Gastric & gastro-oesophageal junction cancer and the tag pipeline.